Rob E. Aarnoutse
YOU?
Author Swipe
View article: Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system Open
Background and objectives Treatment outcomes in Mycobacterium avium complex pulmonary disease may be improved by adding clofazimine, instead of rifampicin, to the azithromycin-ethambutol backbone. Inhalation of clofazimine instead of oral …
View article: Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB
Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB Open
Tuberculous meningitis (TBM) treatment outcomes are poor, partly due to suboptimal drug penetration into the cerebrospinal fluid (CSF). Little is known about the CSF pharmacokinetics of many TB drugs, both established and new. This study i…
View article: Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis Open
Background Tuberculous meningitis (TBM) remains the deadliest form of tuberculosis. Inadequate penetration of rifampicin and ethambutol into the brain and cerebrospinal fluid (CSF) may contribute to mortality. Over the last decade, researc…
View article: The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi
The Acceptability of a Real-Time Medication Monitoring-Based Digital Adherence Tool Among Young People Living with HIV in Malawi Open
Adherence to antiretroviral therapy (ART) is required for young people living with HIV (YPLHIV, 15-24 years) to achieve viral suppression, prevent transmission, and reduce HIV-related morbidity and mortality. Real time medication monitorin…
View article: Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology Open
Objectives Drug concentrations at the site of disease in pulmonary tuberculosis (TB) remain limitedly available, while adequate exposures of anti-TB drugs in the lungs are required for sterilization of lesions. Intrapulmonary concentration…
View article: Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation
Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation Open
We observed marginal differences of QALYs in both the healthcare and societal perspective with cost savings from the healthcare perspective and additional cost from the societal perspective. These mixed results warrant more long-term obser…
View article: Survey on therapeutic drug monitoring practices for nontuberculous mycobacterial Infections: an NTMnet/ESGMYC collaborative study
Survey on therapeutic drug monitoring practices for nontuberculous mycobacterial Infections: an NTMnet/ESGMYC collaborative study Open
View article: Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial Open
EDCTP2 programme funded by the EU; German Ministry for Education and Research; German Center for Infection Research; and Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
View article: Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial Open
LigaChem Biosciences, EDCTP2 programme supported by the EU; German Ministry for Education and Research; German Center for Infection Research; Swiss State Secretariat for Education, Research and Innovation; and Nederlandse Organisatie voor …
View article: Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB Open
Introduction Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinone…
View article: Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients Open
Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observatio…
View article: Medication adherence in patients with nontuberculous mycobacterial disease
Medication adherence in patients with nontuberculous mycobacterial disease Open
View article: Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing
Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing Open
Pharmacogenetics-based and phenotype-based dosing demonstrate greater accuracy in predicting therapeutic nortriptyline plasma concentrations than standard dosing. Further research is warranted to explore the clinical application of model-i…
View article: Engaging community pharmacy in tuberculosis case detection (ENHANCE): a study protocol for an implementation study in Indonesia
Engaging community pharmacy in tuberculosis case detection (ENHANCE): a study protocol for an implementation study in Indonesia Open
View article: Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against <i>Mycobacterium avium</i> in the hollow-fiber system
Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against <i>Mycobacterium avium</i> in the hollow-fiber system Open
Bedaquiline has been proposed as a second-line drug to treat pulmonary disease caused by Mycobacterium avium complex. Based on in vitro synergy and interactions, a logical regimen would combine bedaquiline and clofazimine as additions to a…
View article: Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043
Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043 Open
Introduction BTZ-043 is a first-in-class benzothiazinone for the treatment of TB with demonstrated early bactericidal activity. BTZ-043 is metabolized into two major metabolites: M1 and M2. The aim of this study was to characterize the pha…
View article: Prevalence and Determinants of Viral Suppression in Young People Living with HIV on Antiretroviral Therapy in Southern Africa: A Cross-Sectional Analysis of HIV Survey Data of 2020 and 2021
Prevalence and Determinants of Viral Suppression in Young People Living with HIV on Antiretroviral Therapy in Southern Africa: A Cross-Sectional Analysis of HIV Survey Data of 2020 and 2021 Open
Young People Living with HIV (YPLHIV, 15–24 years) are an important demographic of Persons Living with HIV (PLHIV) globally and in Southern Africa. However, YPLHIV experience poor outcomes across the HIV diagnostic and treatment cascade du…
View article: Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1
Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1 Open
Background/Objectives: Studies show that SNPs in ABCB1 rs2032582 and SLCO1B1 rs4149015 affect the PK profile of moxifloxacin, a key drug for MDR-TB. This study aimed to assess the genotype frequencies of ABCB1 rs2032582 and SLCO1B1 rs41490…
View article: Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age
Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age Open
Background: Isoniazid (INH) remains a first-line drug for the treatment of tuberculosis (TB) in young children. In 2010, the WHO recommended an increase in the daily dose of INH up to 10 (7–15) mg/kg. Currently, there are no INH suspension…
View article: Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial Open
EDCTP2 programme; German Ministry for Education and Research; German Center for Infection Research; InfectControl; Bavarian Ministry for Science and the Arts; Swiss State Secretariat for Education, Research, and Innovation; and Nederlandse…
View article: Medication Adherence in Patients with Nontuberculous Mycobacterial Disease
Medication Adherence in Patients with Nontuberculous Mycobacterial Disease Open
View article: Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system
Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system Open
Replacing rifampicin with minocycline increased the antimycobacterial activity of the MAC-PD treatment regimen in the hollow-fibre model, without jeopardizing the prevention of macrolide-resistance. This promising minocycline-containing re…
View article: Inhaled clofazimine adminsitration increases antimycobacterial effect compared to oral administration in a hollow-fibre system
Inhaled clofazimine adminsitration increases antimycobacterial effect compared to oral administration in a hollow-fibre system Open
AIM: To compare the antimycobacterial effect of inhaled versus oral clofazimine administration with an azithromycin-ethambutol backbone. BACKGROUND: Mycobacterium avium complex causes non-tuberculous pulmonary disease. Clofazimine can repl…
View article: Bedaquiline does not enhance clofazimine treatment efficacy with an azithromycin-ethambutol backbone against Mycobacterium avium in a hollow fibre system
Bedaquiline does not enhance clofazimine treatment efficacy with an azithromycin-ethambutol backbone against Mycobacterium avium in a hollow fibre system Open
AIM: To evaluate the additional pharmacodynamic effect of bedaquiline in a regimen of azithromycin, ethambutol and clofazimine. BACKGROUND: Mycobacterium avium complex bacteria are the most frequent causative agents of nontuberculous mycob…
View article: A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease Open
Objectives Clofazimine is a promising drug for the treatment of nontuberculous mycobacterial (NTM) diseases. Accumulation of clofazimine to reach steady-state plasma concentrations takes months. A loading dose may reduce the time to steady…
View article: Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients
Model-informed dose optimization of mycophenolic acid in pediatric kidney transplant patients Open
View article: Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease
Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease Open
Contains fulltext : 309907.pdf (Publisher’s version ) (Open Access)
View article: Increasing the bioavailability of oral esketamine by a single dose of cobicistat: A case study
Increasing the bioavailability of oral esketamine by a single dose of cobicistat: A case study Open
Background Intranasal esketamine is an approved drug for treatment‐resistant depression (TRD); however, it is costly and may result in specific adverse effects. In this single case study, we explored if oral esketamine can be a suitable al…
View article: Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial
Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial Open
Doubling and tripling the rifampin dose led to three- and four-fold higher exposure compared to standard dose. Pharmacokinetic/pharmacodynamic modelling and simulations are warranted to support trials of shortening the duration of TPT regi…
View article: Correction: A genetic risk score to predict treatment nonresponse in psychotic depression
Correction: A genetic risk score to predict treatment nonresponse in psychotic depression Open